Gene:
ADRB3
adrenoceptor beta 3

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs4994 190T>C, 25681944A>G, 37823798A>G, 5387T>C, ADRB3 T727C, ADRB3:Trp64Arg, Trp64Arg
A > G
Missense
Trp64Arg
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA24598

Details

Cytogenetic Location: chr8 : p12 - p11.23
GP mRNA Boundary: chr8 : 37820513 - 37824184
GP Gene Boundary: chr8 : 37817513 - 37834184
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Thiazides, plain

Curated Information ?

Publications related to ADRB3: 8

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms, hypertension and thiazide diuretics. Pharmacogenomics. 2011. Citterio Lorena, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. Pharmacogenomics. 2011. Risselada Arne J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. The Journal of clinical psychiatry. 2008. Ujike Hiroshi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Estimating coverage and power for genetic association studies using near-complete variation data. Nature genetics. 2008. Bhangale Tushar R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations. Metabolism: clinical and experimental. 2007. Lima John J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evidence for coexistence of three beta-adrenoceptor subtypes in human peripheral lymphocytes. Clinical pharmacology and therapeutics. 2007. Yu Xi-Yong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene. The pharmacogenomics journal. 2005. Iaccarino G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertension research : official journal of the Japanese Society of Hypertension. 2004. Matayoshi Tetsutaro, et al. PubMed

LinkOuts

Entrez Gene:
155
OMIM:
109691
601665
UCSC Genome Browser:
NM_000025
RefSeq RNA:
NM_000025
RefSeq Protein:
NP_000016
RefSeq DNA:
AC_000051
AC_000140
NC_000008
NG_011936
NT_167187
NW_001839128
NW_923907
UniProtKB:
A8KAG8_HUMAN (A8KAG8)
ADRB3_HUMAN (P13945)
Ensembl:
ENSG00000188778
GenAtlas:
ADRB3
GeneCard:
ADRB3
MutDB:
ADRB3
ALFRED:
LO000591P
HuGE:
ADRB3
Comparative Toxicogenomics Database:
155
ModBase:
P13945
IUPHAR Receptor:
β3-adrenoceptor (30)
HGNC:
288

Common Searches